2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5256 Integrated multi-omics challenges the who classification and identifies prognostic subtypes in splenic B-cell lymphoma

Yuting Yan, MD, Bolin Liu2, Runlin An, PhD student3, Weihao Chen4, Xiaoqing Li5, Qianru Zhang6, Yuxi Li, MD7, Zhen Yu, MD8, Wenjie Xiong9, Ying Yu10, Tingyu of Wang11, Rui Lv, MD12, Weiwei Sui13, Wei LIU14, Yan Xu, MD15, Wenyang Huang, MD16, Shuhui Deng17, Qi Sun18, Yujiao Jia, MD19, Jun Wang20, Zhijian Xiao21, Jianxiang Wang Sr, MD, PhD22, Mu Hao23, Huimin Liu24, Xin Du, MD25, Liang Huang, MD26, Dehui Zou, MD27, Gang An, MD28, Lu-Gui Qiu, PhD29, Yuxuan Liu30, Shuhua Yi, DO31
1 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Department of Hematology, Clinical College of Shenzhen Second People's Hospital, Anhui Medical University, Shenzhen, China
6 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
16 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
17 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
18 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
19 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
20 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
21 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
22 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
23 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
24 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
25 Department of Hematology, Clinical College of Shenzhen Second People's Hospital, Anhui Medical University, Shenzhen, China
26 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
27 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
28 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
29 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
30 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
31 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Splenic B-cell lymphomas (SBLs) are heterogeneous neoplasms involving the spleen, peripheral blood, and bone marrow. Overlapping morphologic and immunophenotypic features complicate diagnosis, particularly when splenic tissue is unavailable. Accurate classification is essential because hairy cell leukemia (HCL), hairy cell leukemia variant (HCLv), B-cell prolymphocytic leukemia (B-PLL), splenic marginal zone lymphoma (SMZL), and chronic lymphocytic leukemia (CLL) have distinct outcomes and treatments. The fifth edition of the World Health Organization classification (WHO5) introduced splenic B-cell lymphoma/leukemia with prominent nucleoli (SBLPN), encompassing HCLv and subsets of B-PLL and SMZL, and recognized CLL with prolymphocytic progression (CLL-PP). Whether these revisions reflect precisely molecular disease structure or improve clinically relevant stratification remains uncertain. We evaluated the molecular validity of WHO5 and sought an integrated framework for classification and risk stratification.

Methods: We profiled 287 SBL cases classified by fourth-edition WHO (WHO4) and WHO5 using matched whole-exome sequencing (n=241), bulk RNA sequencing (n=273), single-cell RNA sequencing (n=54), serum proteomics (n=203), and serum metabolomics (n=202).  We sequentially (1) compared WHO4/WHO5 coherence, (2) built a data-driven integrated classification (iWHO), (3) validated iWHO across genomic (somatic mutations and copy-number alterations [CNA]), bulk and single-cell transcriptomic, proteomic, and metabolomic layers, and (4) applied MoCluster integration within the heterogeneous SMZL/HCLv spectrum to resolve clinically relevant subtypes.

Results: Overall survival (OS) differed across WHO5 categories (P=0.001; WHO4, P=0.054), but this separation was not accompanied by greater molecular coherence. SBLPN did not form a discrete molecular entity; instead, it retained HCLv-, B-PLL-, and SMZL-like genomic and transcriptomic profiles, whereas CLL-PP remained closely aligned with CLL. Most reclassified cases more closely resembled their original WHO4 diagnosis than the WHO5 assignment. These findings motivated iWHO, which retained HCL, HCLv, SMZL, and CLL, integrated CLL-PP with CLL, and assigned heterogeneous B-PLL cases to CLL-like or SMZL-like groups by transcriptomic nearest-neighbor voting. Out-of-fold RNA-seq balanced accuracy was 0.87 for iWHO versus 0.74 for WHO4 and 0.68 for WHO5 (n=229); iWHO also increased same-diagnosis neighborhood consistency in single-cell transcriptomic space (P<0.001). Proteomic and metabolomic profiles supported iWHO, although separation remained incomplete.

Despite greater molecular coherence, iWHO did not stratify OS (P=0.375) or progression-free survival (PFS; P=0.061). To characterize prognostic heterogeneity not captured by iWHO, we applied MoCluster to 99 cases spanning the HCLv/SMZL spectrum and identified three consensus subtypes (CS1-CS3). CS1 was characterized by immune-inflammatory signaling, mutated IGHV, low tumor burden, and the most favorable outcome; CS2 by MYC, cell-cycle, oxidative phosphorylation, and metabolic programs with intermediate outcome; and CS3 by transcriptional attenuation, TP53 alteration, 17p loss, high CNA burden, and the poorest outcome. The subtypes stratified PFS and OS (P<0.001) significantly. Adding CS to a three-factor clinical model based on age, hemoglobin, and IGHV status yielded the largest numerical C-index gains (OS, 0.761 to 0.790; PFS, 0.722 to 0.752), whereas WHO4, WHO5, and iWHO added little. In silico drug-response profiles suggested subtype-specific therapeutic vulnerabilities. A compact 20-feature multi-omics classifier reproduced CS assignments with high cross-validated balanced accuracy (0.944).

Conclusions: In one of the largest multi-omics SBL cohorts assembled to date, analyses across molecular layers support retaining HCLv as a distinct disease entity with a characteristic molecular profile and indicate that the WHO5 SBLPN category encompasses biologically heterogeneous diseases. Integrated multi-omics analysis refines diagnostic boundaries and reveals clinically relevant prognostic heterogeneity not captured by current classifications. Collectively, this reframes SBL as a molecularly resolvable spectrum and provides a translatable foundation for precision diagnosis, risk stratification, and subtype-directed therapy, pending prospective validation.

Yuting Yan, MD: No relevant conflicts of interest to declare.